AngioSoma, Inc. is a clinical-stage regenerative medicine and medical device company dedicated to developing novel therapies for vascular and ischemic diseases. The company’s core focus lies in advancing perivascular and endovascular delivery platforms designed to enhance blood flow, promote tissue regeneration, and support healing in patients with peripheral artery disease, critical limb ischemia, and related vascular conditions. Operating under the ticker OTCMKTS:SOAN, AngioSoma leverages both its proprietary delivery systems and biologic payloads to address significant unmet needs in the treatment of chronic wound healing and ischemia.
Since its inception, AngioSoma has pursued a pipeline-driven approach, combining advanced biomaterials with regenerative cell-based therapies. Its flagship program employs adipose-derived mesenchymal stem cells delivered via a minimally invasive catheter system, which is engineered to localize treatment precisely where new vessel growth is needed. In parallel, the company is developing extracellular matrix scaffolds intended for use in surgical or interventional procedures to support vascular repair and tissue remodeling. Together, these product candidates aim to reduce amputation rates, accelerate healing times, and improve quality of life for patients suffering from severe vascular compromise.
AngioSoma serves a global market with an initial emphasis on North America and Europe, where the prevalence of peripheral arterial disease and chronic wound complications continues to rise. The company maintains active collaborations with leading academic medical centers and contract research organizations to conduct preclinical studies and early-stage clinical trials. By aligning its research and development efforts with regulatory pathways in multiple jurisdictions, AngioSoma seeks to establish a clear route toward product registrations and eventual commercial launch.
Underpinning its scientific endeavors is a management team composed of seasoned professionals from the fields of medical device innovation, cell therapy, and vascular surgery. AngioSoma’s leadership includes experts in regulatory affairs, clinical development, and manufacturing scale-up, all working toward the goal of bringing next-generation vascular therapies to market. With a clear strategic vision and a diversified pipeline, AngioSoma aims to be at the forefront of regenerative solutions for patients in need of advanced vascular care.
AI Generated. May Contain Errors.